Anterior uveitis market seen reaching $0.98 billion by 2030

The anterior uveitis market is projected to grow from $0.57 billion in 2025 to $0.98 billion by 2030, driven by rising autoimmune disease cases, better diagnostics and expanding biologic treatment options. North America held the largest share in 2025, while the report points to faster adoption of targeted eye care and outpatient services.

Why it matters: - The anterior uveitis market is expanding because more patients need diagnosis and treatment for inflammation linked to autoimmune disease. - The market outlook points to rising demand for biologic therapies, precision diagnostics and targeted immunosuppressive care. - Faster detection and better eye care infrastructure can improve treatment access and reduce vision-loss risk.

What happened: - The Business Research Company released its Anterior Uveitis Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report estimates the market will rise from $0.57 billion in 2025 to $0.64 billion in 2026. - The report projects the market will reach $0.98 billion by 2030. - The forecast implies a 11.6% CAGR in 2026 and an 11.2% CAGR through 2030. - North America held the largest share of the global anterior uveitis market in 2025.

The details: - Historical growth was driven by better ophthalmic diagnostic tools, higher prevalence of autoimmune-related eye conditions and wider access to corticosteroid treatments. - Growth also reflected development in eye care infrastructure and more specialized ophthalmology services. - Future growth is expected to come from biologic therapies targeting eye diseases, advanced ophthalmic drug pipelines and investment in inflammatory eye disease research. - The report also cites stronger focus on preserving vision and improved use of diagnostic biomarkers. - Other trends include outpatient eye care expansion and earlier disease detection. - Anterior uveitis is an inflammatory condition affecting the front part of the eye’s middle layer, including the iris and nearby ciliary body. - The condition can follow trauma, such as a blow to the eye or a foreign object. - Anterior uveitis is also associated with rheumatoid arthritis, syphilis, tuberculosis, sarcoidosis and viral infections including herpes simplex, herpes zoster and cytomegalovirus. - Some cases are idiopathic, meaning no clear cause is identified. - The report covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - Autoimmune disease prevalence is the clearest demand signal in the report because anterior uveitis often appears alongside systemic inflammatory disorders. - The market opportunity appears to be shifting from basic steroid treatment toward more targeted and data-driven care. - More outpatient delivery suggests treatment may move closer to routine specialty care rather than hospital-only management. - Arthritis Australia reported in February 2024 that about 562,378 Australians are expected to be living with rheumatoid arthritis by 2025, equal to 14% of the country’s arthritis population.

What's next: - Drug developers and eye-care providers are likely to focus more on biologics, biomarkers and earlier diagnosis. - Regional market competition will probably continue to center on North America, while other regions scale ophthalmology access and infrastructure. - The full report and sample request are available through the company’s sample request page and the full market report.